Intermittent androgen deprivation therapy in patients with prostate cancer:Connecting the dots

doi:10.1016/j.ajur.2017.04.001

Asian Journal of Urology, 2017, 4 (4): 208-222 doi: 10.1016/j.ajur.2017.04.001

Review

Current Issue | Archive | Adv Search

Intermittent androgen deprivation therapy in patients with prostate cancer:Connecting the dots

Per-Anders Abrahamsson

Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden

Abstract
Related Citation (15)

Download:

HTML

PDF (450KB)
Export: BibTeX | EndNote (RIS)

Abstract Intermittent androgen deprivation therapy (IADT) is now being increasingly opted by the treating physicians and patients with prostate cancer. The most common reason driving this is the availability of an off-treatment period to the patients that provides some relief from treatment-related side-effects, and reduced treatment costs. IADT may also delay the progression to castration-resistant prostate cancer. However, the use of IADT in the setting of prostate cancer has not been strongly substantiated by data from clinical trials. Multiple factors seem to contribute towards this inadequacy of supportive data for the use of IADT in patients with prostate cancer, e.g., population characteristics (both demographic and clinical), study design, treatment regimen, on-and off-treatment criteria, duration of active treatment, endpoints, and analysis. The present review article focuses on seven clinical trials that evaluated the efficacy of IADT vs. continuous androgen deprivation therapy for the treatment of prostate cancer. The results from these clinical trials have been discussed in light of the factors that may impact the treatment outcomes, especially the disease (tumor) burden. Based on evidence, potential candidate population for IADT has been suggested along with recommendations for the use of IADT in patients with prostate cancer.

Key words： Continuous androgen deprivation therapy Intermittent androgen deprivation therapy Prostate cancer Study designs and outcomes Tumor burden

Received: 24 July 2016 Published: 26 October 2017

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Per-Anders Abrahamsson

TRENDMD:

Cite this article:

Per-Anders Abrahamsson. Intermittent androgen deprivation therapy in patients with prostate cancer:Connecting the dots[J]. Asian Journal of Urology, 2017, 4(4): 208-222.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2017.04.001 OR http://www.ajurology.com/EN/Y2017/V4/I4/208

[1]	Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17:R305-15.
[2]	Mitin T, Efstathiou JA, Shipley WU. Urological cancer. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol 2012;9:672-3.
[3]	Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE. Androgen deprivation therapy:past, present and future. BJU Int 2012;109(Suppl. 6):1-12.
[4]	Tombal B. A holistic approach to androgen deprivation therapy:treating the cancer without hurting the patient. Urol Int 2009;83:373-8.
[5]	Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW, ADT Survivorship Working Group. Androgen deprivation therapy for prostate cancer:recommendations to improve patient and partner quality of life. J Sex Med 2010;7:2996-3010.
[6]	Walker LM, Robinson JW. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer. J Sex Marital Ther 2010;36:154-65.
[7]	Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer:how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 2011;74:289-93.
[8]	Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer:a systematic review of the literature. Eur Urol 2010;57:49-59.
[9]	Sato N, Gleave M, Bruchovsky N. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58:139-46.
[10]	Akakura K, Bruchovsky N, Goldenberg SI, Rennie PS, Bukley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate specific antigen. Cancer 1993;71:2782-90.
[11]	Bruchovsky N, Klotz L, Crook J, Goldenberg SL. Locally advanced prostate cancer-biochemical results from a prospective phase Ⅱ study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 2007;109:858-67.
[12]	Buchan NC, Goldenberg SL. Intermittent androgen suppression for prostate cancer. Nat Rev Urol 2010;7:552-60.
[13]	Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, et al. Duration of first off-treatment interval is prognostic for time to castrationresistanceanddeathinmenwithbiochemicalrelapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010;28:2668-73.
[14]	Mottet N, Bellmunt J, Briers E, van den Bergh RCN, Bolla M, van Casteren NJ, et al. Guidelines on prostate cancer, update March 2015. Available at:http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf.[Accessed 15 July 2016].
[15]	Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer:data from Southwest Oncology Group Trial 9346(INT-0162). J Clin Oncol 2006;24:3984-90.
[16]	de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer:results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1:163-71.
[17]	Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903.
[18]	Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien GA. 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43:233-9.
[19]	Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314-25.
[20]	Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer:results from a randomized phase 3 Study of the South European Uroncological Group. Eur Urol 2009;55:1269-77.
[21]	Calais da Silva F, Calais da Silva FM, Gonçalves F, Santos A, Kliment J, Whelan P, et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade:results from a randomized phase 3 study by the South European Uroncological Group. Eur Urol 2014;66:232-9.
[22]	Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM, et al. Intermittent hormonal therapy in the treatment of metastatic prostate cancer:a randomized trial. BJU Int 2012;110:1262-9.
[23]	Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL, et al. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomized Finn Prostate Study VⅡ:quality of life and adverse effects. Eur Urol 2013;63:111-20.
[24]	Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 2013;31:549-56.
[25]	Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol 2016;2:453-61.
[26]	Hering F, Rodrigues PRT, Lipay MA, Nesrallah L, Srougi M. Metastatic adenocarcinoma of the prostate:comparison between continuous and intermittent hormonal treatment. Braz J Urol 2000;26:276-82.
[27]	Schasfoort E, Heathcote P, Lock T, Zerbib M, Dijkema M, Vergunst H, et al. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 2003; 169(Suppl. 4):1483a.
[28]	Miller K, Steiner U, Lingnau A, Keilholz U, Witzsch U, Haider A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007;25:18S[abstract 5105].
[29]	Irani J, Celhay O, Hubert J, Bladou F, Ragni E, Trape G, et al. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer:a randomised study. Eur Urol 2008;54:382-91.
[30]	Tunn UW, Canepa G, Kochanowsky A, Kienle E. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis 2012;15:296-302.
[31]	Verhagen PC, Wildhagen MF, Verkerk AM, Vjaters E, Pagi H, Kukk L, et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer:results of a randomized trial. World J Urol 2014;32:1287-94.
[32]	Casas F, Henríquez I, Bejar A, Maldonado X, Alvarez A, González-Sansegundo C. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy:a phase 3 GICOR study. Clin Transl Oncol 2017;19:373-8.
[33]	Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer:a phase 3b randomised study (ICELAND). Eur Urol 2016;69:720-7.
[34]	Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, et al. Risks of serious toxicities from intermittent versus continuous androgen deprivation therapy for advanced prostate cancer:a population based study. J Urol 2017;197:1251-7.
[35]	Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer:a systematic review and meta-analysis. BMC Urol 2014;14:9. http://dx.doi.org/10.1186/1471-2490-14-9.
[36]	Burotto M, Prasad V, Fojo T. Non-inferiority trials:why oncologists must remain wary. Lancet Oncol 2015;16:364-6.
[37]	Hussain M, Tangen C, Higano C, Vogelzang N, Thompson I. Evaluating intermittent androgen-deprivation therapy phase Ⅲ clinical trials:the devil is in the details. J Clin Oncol 2016; 34:280-5.
[38]	Klotz LH, Herr HW, Morse MJ, Whitmore Jr WF. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546-50.
[39]	Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate:a metaanalysis of 1446 patients. BJU Int 2007;99:1056-65.
[40]	D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, et al. Surrogate endpoints for prostate cancerspecific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer:an analysis of two randomized trials. Lancet Oncol 2012;13:189-95.
[41]	Isidori AM, Giannetta E, Pozza C, Bonifacio V, Isidori A. Androgens, cardiovascular disease and osteoporosis. J Endocrinol Invest 2005;28(10 Suppl.):73-9.
[42]	De La Taille A, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91:18-22.
[43]	Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, et al. Intermittent androgen-deprivation therapy in prostate cancer:a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
[44]	Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients:factors predictive of prolonged time off therapy. Oncologist 2000;5:45-52.
[45]	Klotz L. Intermittent androgen deprivation therapy:clarity from confusion. Eur Urol 2013;64:731-3.
[46]	Gleave M, Klotz L, Taneja SS. The continued debate:intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 2009;27:81-6.